30 Years of United Efforts: Conquering Parkinson's with No Fear

Lighting the Way with Research

The World's Second Most Common Neurodegenerative Disease –
CUSABIO Partners with You to Accelerate Target Discovery

April 11, 2026 marks the 30th World Parkinson's Disease Day. As the second most common neurodegenerative disease after Alzheimer's disease, Parkinson's disease affects over 6 million patients worldwide. It is characterized by the progressive loss of dopaminergic neurons in the substantia nigra of the midbrain, leading to motor symptoms such as bradykinesia, tremor, and rigidity, as well as non-motor symptoms including sleep disorders and hyposmia.

In recent years, the proportion of cases diagnosed under the age of 60 has increased significantly, highlighting the complex interplay between genetic and environmental factors. Alpha-synuclein (SNCA) aggregation, LRRK2 mutations, mitochondrial dysfunction, and neuroinflammation (IL-1β, TNF-α) have emerged as the most promising intervention targets in 2026.

CUSABIO offers recombinant proteins, high-sensitivity antibodies, and ELISA kits covering these pathways to support your progress on key therapeutic targets.